X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (15080) 15080
Publication (1295) 1295
Book Review (1284) 1284
Book Chapter (40) 40
Conference Proceeding (32) 32
Magazine Article (16) 16
Dissertation (10) 10
Book / eBook (7) 7
Government Document (1) 1
Newspaper Article (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (14019) 14019
animals (8347) 8347
humans (8246) 8246
male (7502) 7502
indoles - pharmacology (6084) 6084
female (4831) 4831
indoles - administration & dosage (4039) 4039
rats (3881) 3881
indoles - therapeutic use (3623) 3623
pharmacology & pharmacy (3145) 3145
mice (3117) 3117
middle aged (2656) 2656
oncology (2225) 2225
adult (2148) 2148
dose-response relationship, drug (2047) 2047
aged (1987) 1987
indoles - adverse effects (1827) 1827
cancer (1745) 1745
neurosciences (1497) 1497
treatment outcome (1401) 1401
rats, sprague-dawley (1357) 1357
cell line, tumor (1182) 1182
indoles - pharmacokinetics (1176) 1176
indoles - chemistry (1170) 1170
analysis (1139) 1139
time factors (1113) 1113
administration, oral (993) 993
biochemistry & molecular biology (980) 980
disease models, animal (967) 967
indoles (953) 953
care and treatment (940) 940
antineoplastic agents - therapeutic use (923) 923
research (922) 922
expression (920) 920
sunitinib (911) 911
pyrroles - therapeutic use (899) 899
pyrroles - administration & dosage (885) 885
rats, wistar (875) 875
apoptosis (873) 873
abridged index medicus (855) 855
article (809) 809
indoles - metabolism (761) 761
therapy (728) 728
chemistry, medicinal (719) 719
double-blind method (709) 709
antineoplastic agents - administration & dosage (695) 695
drug therapy (683) 683
apoptosis - drug effects (666) 666
enzyme inhibitors - pharmacology (665) 665
carcinoma, renal cell - drug therapy (658) 658
tumors (631) 631
cells (627) 627
in-vitro (622) 622
aged, 80 and over (620) 620
kidney neoplasms - drug therapy (620) 620
in-vivo (615) 615
mice, inbred c57bl (603) 603
cell biology (601) 601
drug administration schedule (595) 595
inhibition (591) 591
antineoplastic agents - pharmacology (589) 589
activation (585) 585
antineoplastic agents - adverse effects (580) 580
cell proliferation - drug effects (577) 577
medicine & public health (575) 575
chemotherapy (568) 568
cells, cultured (561) 561
health aspects (556) 556
pyrroles - adverse effects (556) 556
pyrroles - pharmacology (540) 540
antineoplastic combined chemotherapy protocols - therapeutic use (529) 529
proteins (527) 527
rodents (526) 526
rat (525) 525
indole (520) 520
physiological aspects (520) 520
in vitro techniques (519) 519
efficacy (518) 518
brain (517) 517
pharmacokinetics (517) 517
angiogenesis (513) 513
drug therapy, combination (513) 513
metastasis (513) 513
drugs (508) 508
receptor (496) 496
pharmacology (494) 494
structure-activity relationship (493) 493
endothelial growth-factor (490) 490
tyrosine kinase inhibitor (486) 486
physiology (481) 481
indoles - blood (476) 476
serotonin (475) 475
antineoplastic agents (472) 472
blood pressure - drug effects (469) 469
signal transduction - drug effects (467) 467
clinical neurology (465) 465
drug interactions (465) 465
medicine (451) 451
antimitotic agents (447) 447
research article (445) 445
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (14650) 14650
Russian (105) 105
German (96) 96
Japanese (92) 92
French (59) 59
Chinese (43) 43
Spanish (23) 23
Italian (15) 15
Czech (10) 10
Hungarian (9) 9
Polish (8) 8
Danish (6) 6
Dutch (3) 3
Norwegian (2) 2
Portuguese (2) 2
Romanian (2) 2
Swedish (2) 2
Ukrainian (2) 2
Arabic (1) 1
Croatian (1) 1
Korean (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 04/2018, Volume 378, Issue 14, pp. 1277 - 1290
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In healthy subjects, GSK2248761 was shown to be safe and well tolerated with single doses up to 1200 mg once daily... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | Index Medicus | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis | Index Medicus
Journal Article
European Journal of Heart Failure, ISSN 1388-9842, 08/2005, Volume 7, Issue 5, pp. 710 - 721
Surveys of prescribing patterns in both hospitals and primary care have usually shown delays in translating the evidence from clinical trials of... 
Heart failure | Isosorbide dinitrate | Beta‐blockers | Digoxin | Angiotensin receptor blockers | Pharmacology | Aldosterone antagonists | Treatment | Eplerenone | Spironolactone | Hydralazine | ACE inhibitors | Clinical recommendations | Beta-blockers | VENTRICULAR SYSTOLIC DYSFUNCTION | heart failure | treatment | CARDIAC & CARDIOVASCULAR SYSTEMS | angiotensin receptor blockers | QUALITY-OF-CARE | hydralazine | eplerenone | isosorbide dinitrate | RANDOMIZED INTERVENTION TRIAL | beta-blockers | MEDICAL-TREATMENT | GENERAL-PRACTICE | digoxin | spironolactone | CONVERTING-ENZYME-INHIBITORS | clinical recommendations | CARDIAC-INSUFFICIENCY | pharmacology | NATIONAL-SURVEY | aldosterone antagonists | ELDERLY-PATIENTS | Benzopyrans - therapeutic use | Valsartan | Angiotensin Receptor Antagonists | Bisoprolol - therapeutic use | Humans | Carbazoles - administration & dosage | Heart Failure - physiopathology | Valine - administration & dosage | Enalapril - therapeutic use | Ethanolamines - administration & dosage | Indoles - administration & dosage | Ramipril - administration & dosage | Captopril - therapeutic use | Propanolamines - therapeutic use | Lisinopril - therapeutic use | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Benzimidazoles - administration & dosage | Tetrazoles - administration & dosage | Ramipril - therapeutic use | Drug Therapy, Combination | Enalapril - administration & dosage | Spironolactone - therapeutic use | Adrenergic beta-Antagonists - administration & dosage | Adrenergic beta-Antagonists - therapeutic use | Benzimidazoles - therapeutic use | Lisinopril - administration & dosage | Nebivolol | Valine - analogs & derivatives | Metoprolol - therapeutic use | Metoprolol - administration & dosage | Evidence-Based Medicine | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Bisoprolol - administration & dosage | Heart Failure - drug therapy | Mineralocorticoid Receptor Antagonists - therapeutic use | Stroke Volume | Benzopyrans - administration & dosage | Captopril - administration & dosage | Guideline Adherence | Ethanolamines - therapeutic use | Indoles - therapeutic use | Metoprolol - analogs & derivatives | Tetrazoles - therapeutic use | Valine - therapeutic use | Carbazoles - therapeutic use | Propanolamines - administration & dosage | Practice Guidelines as Topic | Prescription writing | Corticosteroids | Isosorbide mononitrate | Family medicine | Nitrates | Peptide hormones | Aldosterone | Preventive health services | Cardiac patients | Angiotensin | Antiandrogens | Medicine, Preventive | Steroids | Index Medicus | Kardiologi | converting-enzyme-inhibitors | Cardiac and Cardiovascular Systems | randomized intervention trial | quality-of-care | elderly-patients | cardiac-insufficiency | national-survey | medical-treatment | ventricular systolic dysfunction | general-practice
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10032, pp. 2008 - 2016
Journal Article
Theranostics, ISSN 1838-7640, 2016, Volume 6, Issue 7, pp. 1031 - 1042
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9829, pp. 1893 - 1901
Summary Background Dabrafenib is an inhibitor of BRAF kinase that is selective for mutant BRAF. We aimed to assess its safety and tolerability and to establish... 
Internal Medicine | SURVIVAL | IRRADIATION | MEDICINE, GENERAL & INTERNAL | PATHWAY | RAF INHIBITOR RESISTANCE | B-RAF | MUTATIONS | CANCER | BRAF(V600E) | VEMURAFENIB | Oximes - adverse effects | Humans | Middle Aged | Carcinoma, Squamous Cell - chemically induced | Oximes - administration & dosage | Imidazoles - administration & dosage | Male | Fatigue - chemically induced | Antineoplastic Agents - administration & dosage | Fever - chemically induced | Indoles - administration & dosage | Brain Neoplasms - secondary | Neoplasms - genetics | Antineoplastic Agents - adverse effects | Melanoma - genetics | Adult | Female | Drug Administration Schedule | Imidazoles - adverse effects | Genotype | Treatment Outcome | Skin Neoplasms - chemically induced | Brain Neoplasms - drug therapy | Mutation - genetics | Melanoma - secondary | Neoplasms - drug therapy | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Maximum Tolerated Dose | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Sulfonamides - adverse effects | Sulfonamides - administration & dosage | Antimitotic agents | Complications and side effects | Melanoma | Dosage and administration | Metastasis | Antineoplastic agents | Drug therapy | Clinical trials | Medical research | Chemotherapy | Mutation | Toxicity | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 02/2016, Volume 122, Issue 3, pp. 411 - 419
Toxicities associated with vascular endothelial growth factor–targeted therapies can often compromise clinical benefit in patients with metastatic renal cell... 
International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) | toxicity | renal cell carcinoma | risk factors | treatment discontinuation | model | VEGF‐targeted therapies | VEGF-targeted therapies | SAFETY | OLDER-ADULTS | PHASE-III | SORAFENIB | CANCER | INTERFERON-ALPHA | ANGIOGENESIS INHIBITOR THERAPIES | ONCOLOGY | TREATMENT PATTERNS | SUNITINIB | CLINICAL-PRACTICE | Predictive Value of Tests | Humans | Middle Aged | Male | Fatigue - chemically induced | Kidney Neoplasms - metabolism | Antineoplastic Agents - administration & dosage | Hand-Foot Syndrome - etiology | Indazoles - administration & dosage | Indoles - administration & dosage | Kidney Neoplasms - blood | Pyrroles - administration & dosage | Aged, 80 and over | Pyrroles - adverse effects | Bevacizumab - administration & dosage | Risk Assessment | Imidazoles - adverse effects | Risk Factors | Niacinamide - adverse effects | Mucositis - chemically induced | Carcinoma, Renal Cell - metabolism | Indoles - adverse effects | Indazoles - adverse effects | Sulfonamides - administration & dosage | Niacinamide - analogs & derivatives | Bevacizumab - adverse effects | Imidazoles - administration & dosage | Diarrhea - chemically induced | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Female | Retrospective Studies | Vascular Endothelial Growth Factor A - drug effects | Carcinoma, Renal Cell - drug therapy | Molecular Targeted Therapy - methods | Databases, Factual | Molecular Targeted Therapy - adverse effects | Carcinoma, Renal Cell - blood | Drug Administration Schedule | Pyrimidines - administration & dosage | Kaplan-Meier Estimate | Models, Statistical | Niacinamide - administration & dosage | Phenylurea Compounds - administration & dosage | Carcinoma, Renal Cell - secondary | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Care and treatment | Dosage and administration | Carcinoma, Renal cell | Diagnosis | Vascular endothelial growth factor | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 11, pp. 1195 - 1206
Journal Article